Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients at high cardiovascular risk |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percent rate of patients achieving target LDL cholesterol goals | On each of the 3 visits performed during the study | |
| Percent rate of patients achieving 50% or more reduction in LDL-cholesterol | On each of the 3 visits performed during the study |
| Measure | Description | Time Frame |
|---|---|---|
| Percent rate of patients achieving target secondary (total Ch, triglycerides, HDL Ch) goals | On each of the 3 visits performed during the study | |
| Percent rate of compliance among patients in the study | On each of the 3 visits performed during the study |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Ambulatory clinics
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mark Laszlo, MD, PHD | County Hospital Bekes, Gyula | Principal Investigator |
| Csaba Csongvai, MD | AstraZeneca Hungary | Study Director |
| Eva Gulyas | AstraZeneca Hungary | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Baja | Hungary | ||||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 7968073 | Background | Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9. | |
| 7566020 | Background | Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301-7. doi: 10.1056/NEJM199511163332001. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Békéscsaba |
| Hungary |
| Research Site | Budapest | Hungary |
| Research Site | Budapest III District | Hungary |
| Research Site | Cegléd | Hungary |
| Research Site | Debrecen | Hungary |
| Research Site | Gyöngyös | Hungary |
| Research Site | Gyula | Hungary |
| Research Site | Jászberény | Hungary |
| Research Site | Kalocsa | Hungary |
| Research Site | Karcag | Hungary |
| Research Site | Kecskemét | Hungary |
| Research Site | Kisvárda | Hungary |
| Research Site | Mohács | Hungary |
| Research Site | Nyíregyháza | Hungary |
| Research Site | Orosháza | Hungary |
| Research Site | Pásztó | Hungary |
| Research Site | Püspökladány | Hungary |
| Research Site | Salgótarján | Hungary |
| Research Site | Szarvas | Hungary |
| Research Site | Szekszárd | Hungary |
| Research Site | Szécsény | Hungary |
| Research Site | Székesfehérvár | Hungary |
| Research Site | Szolnok | Hungary |
| Research Site | Tatabánya | Hungary |
| Research Site | Vác | Hungary |
| 8801446 | Background | Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001-9. doi: 10.1056/NEJM199610033351401. |
| 9841303 | Background | Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 Nov 5;339(19):1349-57. doi: 10.1056/NEJM199811053391902. |
| 9613910 | Background | Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615-22. doi: 10.1001/jama.279.20.1615. |
| 12114036 | Background | Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3. |
| 12964575 | Background | De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003 Sep;24(17):1601-10. doi: 10.1016/s0195-668x(03)00347-6. No abstract available. |